Giants lefty Carson Whisenhunt set for UCL surgery, timeline expected to run into 2028

San Francisco Giants left-handed pitcher Carson Whisenhunt is expected to undergo surgery on his left elbow ulnar collateral ligament, a development that likely reshapes the team’s pitching plans for the next two seasons. Multiple reports indicate Whisenhunt has a torn UCL and is working through a decision process on what kind of repair will be performed, a fork in the road that can affect both recovery length and how confidently a pitcher returns to live-game intensity.

According to Alex Pavlovic of NBC Sports Bay Area, Whisenhunt will undergo UCL surgery after sustaining a tear in the ligament that is critical to how pitchers generate torque and stability in their throwing arm. Susan Slusser of the San Francisco Chronicle also reported that he is getting one more medical opinion before the procedure, which suggests the Giants are trying to ensure the choice between a more limited repair option and a full reconstruction is grounded in consistent evaluations from specialists.

The key decision centers on whether Whisenhunt will receive an internal brace procedure or a full reconstruction often associated with Tommy John surgery. The distinction is significant because it can change the standard medical timeline. As characterized in reporting from MLB Trade Rumors, the internal brace route would generally be associated with a somewhat quicker path back compared with reconstruction, but it still commonly requires a lengthy bullpen-to-game progression and does not remove the risk of further setbacks during rehab.

Even with the hope that an internal brace might shorten the return window, the expectations described in the reporting are still lengthy. MLB Trade Rumors reported that either approach would likely sideline Whisenhunt for all of the 2027 season, with an internal brace leaving a narrow possibility of a return late in September of the following year. That is a wide range of outcomes, but the common thread is that the injury is serious enough to remove him from near-term major-league planning.

For the Giants, the timing arrives at a moment when organizational pitching depth is often evaluated through the availability of controllable arms and the ability to bridge development years into major-league roles. A season-spanning absence for a young pitcher affects both the immediate workload picture and the longer-term pipeline, especially when teams are balancing bullpen needs with the development of prospects in the minors.

From Whisenhunt’s perspective, the surgery decision is also about long-term durability. Pitchers and teams weigh not only how soon a player can resume throwing, but whether the chosen procedure best supports a stable return to mechanics and command. With the report indicating another opinion is forthcoming or recently obtained, the Giants appear to be prioritizing the clarity needed to reduce uncertainty around the exact structural injury and the most reliable path back.

The next thing to watch is the medical resolution itself: which procedure is ultimately selected, and how the subsequent rehab plan is structured. In the weeks after UCL surgery, teams typically monitor early progression milestones before discussing any realistic return windows. For San Francisco, updates on Whisenhunt’s timetable will also influence how the club evaluates the remaining pitching options for the 2027 roster and how it plans minor-league assignments during his absence.